AbbVie, Roche’s Venclexta stumbles amid patient deaths in multiple myeloma trial
AbbVie said Tuesday that the FDA had placed a partial clinical hold on all Venclexta studies in myeloma due to a higher rate of deaths in the Phase III BELLINI study.
AbbVie said Tuesday that the FDA had placed a partial clinical hold on all Venclexta studies in myeloma due to a higher rate of deaths in the Phase III BELLINI study.